I-Tsyr Shaw
Endocrinology, Diabetes & Metabolism · Sacramento, CANPI 1104026558
Payments from drug & device makers
Across 128 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$588
- Lilly USA, LLC$444
- Tandem Diabetes Care, Inc.$337
- Abbott$327
- Insulet Corporation$187
- Amgen$166
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$30010%
- Food & beverage$2,83790%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $588 |
| Lilly USA, LLC | 26 | $444 |
| Tandem Diabetes Care, Inc. | 2 | $337 |
| Abbott | 12 | $327 |
| Insulet Corporation | 5 | $187 |
| Amgen | 8 | $166 |
| Merck | 8 | $164 |
| Boehringer Ingelheim | 6 | $102 |
| Xeris Pharmaceuticals, Inc. | 4 | $86 |
| Bayer | 3 | $74 |
| Sanofi Pasteur Inc. | 2 | $72 |
| Antares Pharma, Inc. | 3 | $66 |
| Amarin Pharma, Inc. | 3 | $64 |
| Ascendis Pharma Endocrinology Inc | 2 | $57 |
| Dexcom, Inc. | 2 | $56 |
| Medtronic(2 entities) | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Mannkind Corporation | 2 | $44 |
| Radius Health, Inc. | 2 | $43 |
| Halozyme Inc | 2 | $36 |
| Phadia US Inc. | 2 | $32 |
| Exact Sciences | 1 | $31 |
| Alkermes, Inc. | 1 | $20 |
| LNHC, Inc | 1 | $15 |
| BD | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,137 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 533 | $614,979 |
| JardianceEmpagliflozin | 272 | $262,822 |
| TrulicityDulaglutide | 91 | $118,544 |
| JanuviaSitagliptin Phosphate | 122 | $103,459 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 242 | $100,676 |
| RybelsusSemaglutide | 46 | $55,938 |
| MounjaroTirzepatide | 48 | $52,154 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $49,704 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $41,511 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 316 | $40,177 |
| TradjentaLinagliptin | 47 | $39,922 |
| Humalog Kwikpen U-100Insulin Lispro | 169 | $37,921 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $33,530 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $23,155 |
| FarxigaDapagliflozin Propanediol | 20 | $18,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $588 | $670,916579 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $102 | $315,295334 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $444 | $174,086157 claims |
| MerckJanuvia, Janumet | $164 | $116,334135 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $3,38023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Sacramento
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.